Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Gains from Investment Securities: 2013-2022

Historic Gains from Investment Securities for Avadel Pharmaceuticals (AVDL) over the last 6 years, with Dec 2022 value amounting to $3.3 million.

  • Avadel Pharmaceuticals' Gains from Investment Securities rose 40712.50% to $3.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$29.1 million, marking a year-over-year decrease of 17922.09%. This contributed to the annual value of -$29.1 million for FY2022, which is 38334.21% down from last year.
  • According to the latest figures from Q4 2022, Avadel Pharmaceuticals' Gains from Investment Securities is $3.3 million, which was up 117.91% from -$18.2 million recorded in Q3 2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Gains from Investment Securities peaked at $3.3 million during Q4 2022, and registered a low of -$18.2 million during Q3 2022.
  • In the last 3 years, Avadel Pharmaceuticals' Gains from Investment Securities had a median value of $7,000 in 2021 and averaged -$3.4 million.
  • Data for Avadel Pharmaceuticals' Gains from Investment Securities shows a peak YoY increase of 40,712.50% (in 2022) and a maximum YoY decrease of 201,471.43% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Gains from Investment Securities stood at $776,000 in 2018, then declined by 20.36% to $618,000 in 2019, then tumbled by 85.92% to $87,000 in 2020, then slumped by 90.80% to $8,000 in 2021, then surged by 40,712.50% to $3.3 million in 2022.
  • Its Gains from Investment Securities stands at $3.3 million for Q4 2022, versus -$18.2 million for Q3 2022 and -$14.1 million for Q2 2022.